Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Treatment combinations in Hodgkin lymphoma

Pauline Brice • 26 Mar 2019
EBMT 2019
Hodgkin Lymphoma Lymphoma Brentuximab vedotin Checkpoint inhibitors

Pauline Brice, MD, PhD, of Hopital Saint-Louis, Paris, France, discusses combination therapies for Hodgkin lymphoma. Dr Brice was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Pauline Brice

2:08
Cellular and targeted therapies for Hodgkin lymphoma
Pauline Brice • 26 Mar 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals